Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 11/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.56 |
| ▸ | RET | P07949 | 4/20 | 0.56 |
| ▸ | FLT1 | P17948 | 2/20 | 0.54 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 2/20 | 0.53 |
| ▸ | LCK | P06239 | 2/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | STK10 | O94804 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.52 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.52 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.52 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1838804 | 0.94 | KDR (0.58) | KDREPHA2ERBB2EGFRLRRK2 | |
| SCHEMBL1707535 | 0.90 | KDR (0.61) | KDREPHA2ERBB2EGFRLRRK2 | |
| SCHEMBL1707497 | 0.90 | LRRK2 (0.55) | KDREPHA2ERBB2EGFRLRRK2 | |
| SCHEMBL1706728 | 0.87 | EGFR (0.54) | KDREPHA2ERBB2EGFRLRRK2 | |
| SCHEMBL1707085 | 0.86 | LRRK2 (0.49) | KDREPHA2ERBB2EGFRLRRK2 | |
| SCHEMBL1707254 | 0.85 | EGFR (0.70) | KDREGFRLRRK2RETFLT1 | |
| SCHEMBL10230929 | 0.85 | LRRK2 (0.48) | KDREPHA2ERBB2EGFRLRRK2 | |
| SCHEMBL1707225 | 0.85 | EGFR (0.53) | KDREPHA2ERBB2EGFRLRRK2 | |
| SCHEMBL1706637 | 0.84 | EGFR (0.50) | KDREGFRLRRK2RETGAK | |
| SCHEMBL2183476 | 0.84 | KDR (0.62) | KDREPHA2ERBB2EGFRLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | claimed |
| EP-2247579-B1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | Bayer Pharma AG (DE) | 2012-04-18 | — | — | EP | disclosed |
| EP-2247579-B1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | Bayer Pharma AG (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| WO-2009089851-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-23 | — | — | WO | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | IFNG, TPMT, IRF3 | KDR 3554/4885EPHA2 4368/4885ERBB2 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.